

Prescribing Clinical Network

Policy Statement	Dosulepin for the treatment of neuropathic pain
Policy No:	PCN 226-2016
Date of Issue	November 2016
Review Date:	November 2019 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
Recommendations: The PCN does not recommend the use of 'off label' dosulepin for the treatment of neuropathic pain and it will be considered BLACK on the traffic light system	
Key Consideration: - NICE guidance (CG173 November 2013) Neuropathic pain in adults: Pharmacological management in non-specialist settings, recommends the use of amitriptyline as an initial treatment option but does not include other tricyclic antidepressants (TCAs). It recommends a switch to another class of drug if amitriptyline is not tolerated or contra-indicated. https://www.nice.org.uk/guidance/cg173/chapter/1-recommendations	
Date taken to Prescribing Clinical Network	2 nd November 2016
Agreed by PCN members	18 th November 2016